Reactive oxygen species (ROS) are produced in the human body and are believed to be a cause of chronic disease progression (
1). Under normal physiological conditions, ROS level is low enough to be efficiently eliminated by antioxidative defense mechanisms, including superoxide dismutase, glutathione reductase, glutathione peroxidase, and catalase. The function of ROS, as defending enzymes, is well established and has been widely investigated (
2,
3). Nevertheless, an imbalance in this mechanism in favor of ROS overproduction leads to oxidative stress, which plays an influential role in the etiology of many chronic diseases, including cardiovascular diseases, neurodegenerative diseases, diabetes, and cancer (
4).
Human hepatoma cell lines (HepG
2), which are distinctively transformed, well differentiated cell lines from hepatic origins, have been utilized for the enhancement of cell-oriented bioassays in the analysis of drug antioxidant activity (
5). Also, A549, a human lung adenocarcinoma cell line, has been introduced in an in vitro model of alveolar epithelium type II by Foster and colleagues (
6). Hydrogen peroxide (H
2O
2), as a major ROS, has been widely used as an activator of oxidative stress in such models (
7). Therefore, treating HepG
2 and non-small-cell lung cancer A549 cells with H
2O
2 can act as a model for assessing the antioxidant activity of novel compounds.
Furthermore, a range of natural products have been shown to have potential protective effects against chronic diseases (
8,
9). Generally, the main objective is to highlight the role of some natural products which ameliorate oxidative stress and reduce pathological complications, related to chronic diseases. In this regard, H. Kalantari et al. reported that
Morus alba L. and
Ficus carica leaf extracts can improve the protective capacity against CCl
4-induced oxidative damage in mice (
10,
11).
Angipars™ is a registered drug, extracted from
Melilotus officinalis through electromagnetic processes. It contains compounds, including 7-hydroxycoumarin and flavonoids and is available in markets in form of a suspension in 9.2% ethanol. Angipars™ has accepted safety and has been assessed in clinical trials; in fact, it has been registered as the first-line treatment for human diabetic foot ulcer (
12-
15). The major compound of this drug, coumarin, is recognized for its anti-inflammatory and antioxidant properties and has the capacity to inhibit superoxide and nitric oxide production in leukocytes, thereby, reducing the phagocyte activity (
16).